AMBP inhibitors belong to a distinctive chemical class that primarily targets the alpha-1-microglobulin/bikunin precursor (AMBP) protein. The AMBP protein, also known as inter-alpha-trypsin inhibitor (ITI), plays a crucial role in various physiological processes, particularly in modulating inflammation and tissue repair. This class of inhibitors is characterized by their ability to selectively interact with AMBP, impeding its normal functions. AMBP itself is a complex multifunctional glycoprotein composed of multiple protein components, with bikunin being a prominent constituent. Bikunin, in turn, is involved in the inhibition of various proteases, contributing to the regulation of proteolytic activities.
AMBP inhibitors typically possess key molecular features that enable them to bind to specific regions of the AMBP protein, thereby disrupting its interactions and subsequent downstream effects. The development of AMBP inhibitors involves a deep understanding of the molecular interactions between the inhibitor and the target protein, allowing for the design of compounds with enhanced binding affinity and selectivity. Researchers in this field aim to elucidate the intricate biochemical mechanisms underlying the AMBP protein's functions and its involvement in various physiological processes. By selectively inhibiting AMBP, this chemical class holds promise for advancing our understanding of complex biological pathways and may pave the way for novel research directions in the broader field of molecular biology and biochemistry.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib can inhibit multiple kinases involved in cell proliferation and angiogenesis, which may indirectly affect AMBP-related pathways. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that may interfere with AMBP-related pathways through its anti-angiogenic effects. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
ZD6474 is a tyrosine kinase inhibitor that can impact EGFR and VEGFR2, potentially affecting AMBP-related pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib inhibits several tyrosine kinases, which can possibly affect the signaling pathways that involve AMBP. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib can inhibit EGFR tyrosine kinase, which may indirectly influence AMBP-related pathways. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib can inhibit EGFR, potentially affecting AMBP-related pathways. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib can interfere with EGFR and HER2/neu, which may indirectly impact AMBP-related pathways. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib inhibits BCR-ABL, c-KIT, and PDGFR, which can possibly affect the signaling pathways that involve AMBP. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Pazopanib is a multi-kinase inhibitor that can potentially affect AMBP-related pathways. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Lenvatinib can inhibit VEGFR2 tyrosine kinase, possibly affecting AMBP-related pathways. | ||||||